We are analyzing https://link.springer.com/article/10.1007/s12032-010-9572-6.

Title:
More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin | Medical Oncology
Description:
The coexistence of type 2 diabetes with breast cancer may result in poorer cancer-related survival due to a number of mediating factors including an alteration of tumor tissue hormonal sensitivity. Previous studies have shown that receptor status of breast tumors in diabetics may be changed; however, the mode of therapy for diabetes was usually ignored. This work presents the results of an analysis of the receptor status of breast carcinomas in 90 postmenopausal women suffering with diabetes mellitus type 2 who had been cured, for not less that 1 year prior to surgery, with different modes of antidiabetic therapy, including a dietary treatment only, sulfonylurea preparations, insulin therapy, and metformin as a monotherapy or in combination with sulfonylurea derivatives. No differences in estrogen receptors occurrence in tumor tissue were found in different treatment groups. The frequency of progesterone receptor-positive mammary carcinomas in women who were treated with metformin, irrespective of whether it was combined with sulfonylurea preparations, was significantly higher than in the sulfonylurea only group (P = 0.043) and in the combined group of patients treated with either sulfonylurea or insulin (P = 0.041). The exclusion of the patients who received neoadjuvant chemotherapy (24 persons) did not significantly affect the above results. The data may be used as an explanation of the distinctions in cancer characteristics and course between diabetic patients treated with either metformin or sulfonylurea derivatives and insulin.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Insurance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

cancer, article, google, scholar, breast, pubmed, diabetes, cas, metformin, receptor, type, oncol, berstein, patients, sulfonylurea, study, research, progesterone, treated, status, treatment, insulin, clin, privacy, cookies, content, therapy, women, diabetic, access, hormone, analysis, data, publish, search, tsyrlina, mellitus, antidiabetic, estrogen, risk, endocrinology, springer, including, information, log, journal, oncology, phenotype, diabetics, lev,

Topics {✒️}

month download article/chapter real-world cohort study extracellular signal-regulated kinase amp-activated protein kinase increased cancer-related mortality receptor-negative breast cancer endocrine-responsive cancer full article pdf hormone receptor status related subjects progesterone receptor expression privacy choices/manage cookies progesterone receptor levels estrogen receptors occurrence hypothesis-generating study nurses’ health study case-control study larsen pr simpson er petrov research institute hormone receptors human breast adenocarcinoma lower cancer mortality metformin inhibits aromatase article berstein european economic area check access wb saunders comp glucose-lowering therapies pathologic complete responses instant access early breast cancer insulin-lowering effects conditions privacy policy vasil’ev da clin breast cancer oral antidiabetic agents article log accepting optional cookies mediating factors including breast cancer risk insulin therapy received neoadjuvant chemotherapy author information authors receptor status potential role article cite journal finder publish type 2 diabetes clinical research

Questions {❓}

Is it time to test metformin in breast cancer clinical trials?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin
         description:The coexistence of type 2 diabetes with breast cancer may result in poorer cancer-related survival due to a number of mediating factors including an alteration of tumor tissue hormonal sensitivity. Previous studies have shown that receptor status of breast tumors in diabetics may be changed; however, the mode of therapy for diabetes was usually ignored. This work presents the results of an analysis of the receptor status of breast carcinomas in 90 postmenopausal women suffering with diabetes mellitus type 2 who had been cured, for not less that 1 year prior to surgery, with different modes of antidiabetic therapy, including a dietary treatment only, sulfonylurea preparations, insulin therapy, and metformin as a monotherapy or in combination with sulfonylurea derivatives. No differences in estrogen receptors occurrence in tumor tissue were found in different treatment groups. The frequency of progesterone receptor-positive mammary carcinomas in women who were treated with metformin, irrespective of whether it was combined with sulfonylurea preparations, was significantly higher than in the sulfonylurea only group (P = 0.043) and in the combined group of patients treated with either sulfonylurea or insulin (P = 0.041). The exclusion of the patients who received neoadjuvant chemotherapy (24 persons) did not significantly affect the above results. The data may be used as an explanation of the distinctions in cancer characteristics and course between diabetic patients treated with either metformin or sulfonylurea derivatives and insulin.
         datePublished:2010-05-20T00:00:00Z
         dateModified:2010-05-20T00:00:00Z
         pageStart:1260
         pageEnd:1263
         sameAs:https://doi.org/10.1007/s12032-010-9572-6
         keywords:
            Breast cancer
            Receptor phenotype
            ER
            PR
            Diabetes treatment
            Metformin
            Sulphonylurea
            Insulin therapy
            Oncology
            Hematology
            Pathology
            Internal Medicine
         image:
         isPartOf:
            name:Medical Oncology
            issn:
               1559-131X
               1357-0560
            volumeNumber:28
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Lev M. Berstein
               affiliation:
                     name:N. N. Petrov Research Institute of Oncology
                     address:
                        name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Marina P. Boyarkina
               affiliation:
                     name:N. N. Petrov Research Institute of Oncology
                     address:
                        name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Evgenia V. Tsyrlina
               affiliation:
                     name:N. N. Petrov Research Institute of Oncology
                     address:
                        name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Elena A. Turkevich
               affiliation:
                     name:N. N. Petrov Research Institute of Oncology
                     address:
                        name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Vladimir F. Semiglazov
               affiliation:
                     name:N. N. Petrov Research Institute of Oncology
                     address:
                        name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin
      description:The coexistence of type 2 diabetes with breast cancer may result in poorer cancer-related survival due to a number of mediating factors including an alteration of tumor tissue hormonal sensitivity. Previous studies have shown that receptor status of breast tumors in diabetics may be changed; however, the mode of therapy for diabetes was usually ignored. This work presents the results of an analysis of the receptor status of breast carcinomas in 90 postmenopausal women suffering with diabetes mellitus type 2 who had been cured, for not less that 1 year prior to surgery, with different modes of antidiabetic therapy, including a dietary treatment only, sulfonylurea preparations, insulin therapy, and metformin as a monotherapy or in combination with sulfonylurea derivatives. No differences in estrogen receptors occurrence in tumor tissue were found in different treatment groups. The frequency of progesterone receptor-positive mammary carcinomas in women who were treated with metformin, irrespective of whether it was combined with sulfonylurea preparations, was significantly higher than in the sulfonylurea only group (P = 0.043) and in the combined group of patients treated with either sulfonylurea or insulin (P = 0.041). The exclusion of the patients who received neoadjuvant chemotherapy (24 persons) did not significantly affect the above results. The data may be used as an explanation of the distinctions in cancer characteristics and course between diabetic patients treated with either metformin or sulfonylurea derivatives and insulin.
      datePublished:2010-05-20T00:00:00Z
      dateModified:2010-05-20T00:00:00Z
      pageStart:1260
      pageEnd:1263
      sameAs:https://doi.org/10.1007/s12032-010-9572-6
      keywords:
         Breast cancer
         Receptor phenotype
         ER
         PR
         Diabetes treatment
         Metformin
         Sulphonylurea
         Insulin therapy
         Oncology
         Hematology
         Pathology
         Internal Medicine
      image:
      isPartOf:
         name:Medical Oncology
         issn:
            1559-131X
            1357-0560
         volumeNumber:28
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Lev M. Berstein
            affiliation:
                  name:N. N. Petrov Research Institute of Oncology
                  address:
                     name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Marina P. Boyarkina
            affiliation:
                  name:N. N. Petrov Research Institute of Oncology
                  address:
                     name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Evgenia V. Tsyrlina
            affiliation:
                  name:N. N. Petrov Research Institute of Oncology
                  address:
                     name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Elena A. Turkevich
            affiliation:
                  name:N. N. Petrov Research Institute of Oncology
                  address:
                     name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Vladimir F. Semiglazov
            affiliation:
                  name:N. N. Petrov Research Institute of Oncology
                  address:
                     name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Medical Oncology
      issn:
         1559-131X
         1357-0560
      volumeNumber:28
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:N. N. Petrov Research Institute of Oncology
      address:
         name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
         type:PostalAddress
      name:N. N. Petrov Research Institute of Oncology
      address:
         name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
         type:PostalAddress
      name:N. N. Petrov Research Institute of Oncology
      address:
         name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
         type:PostalAddress
      name:N. N. Petrov Research Institute of Oncology
      address:
         name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
         type:PostalAddress
      name:N. N. Petrov Research Institute of Oncology
      address:
         name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Lev M. Berstein
      affiliation:
            name:N. N. Petrov Research Institute of Oncology
            address:
               name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Marina P. Boyarkina
      affiliation:
            name:N. N. Petrov Research Institute of Oncology
            address:
               name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
               type:PostalAddress
            type:Organization
      name:Evgenia V. Tsyrlina
      affiliation:
            name:N. N. Petrov Research Institute of Oncology
            address:
               name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
               type:PostalAddress
            type:Organization
      name:Elena A. Turkevich
      affiliation:
            name:N. N. Petrov Research Institute of Oncology
            address:
               name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
               type:PostalAddress
            type:Organization
      name:Vladimir F. Semiglazov
      affiliation:
            name:N. N. Petrov Research Institute of Oncology
            address:
               name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
               type:PostalAddress
            type:Organization
PostalAddress:
      name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
      name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
      name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
      name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
      name:N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(115)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.9s.

LINK . SPRINGER . COM {}